Oncternal Therapeutics, Inc. ONCT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
40/100
Developing

Ranked against 712 peers in Biotechnology

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.78), suggesting sticky customer base.
  • Strong Liquidity Buffer Liquidity position is strong (score 0.67), providing operational cushion.

Key risks

  • Commodity Pressure / Weak Differentiation Gross margin at 2.5th percentile with high volatility suggests weak pricing power or commoditized products.
  • Scale Without Profitability Despite scale, profitability lags peers (score 0.12), suggesting limited competitive advantage.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
19
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ONCT ranks in Biotechnology

Oncternal Therapeutics, Inc. ranks #368 of 713 scored companies in Biotechnology by moat score — the top 52%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
364 Coherus BioSciences, Inc. CHRS 41/100 Developing
365 ProMIS Neurosciences Inc. PMN 41/100 Developing
366 Shattuck Labs, Inc. STTK 40/100 Developing
367 BeyondSpring, Inc. BYSI 40/100 Developing
368 Oncternal Therapeutics, Inc. ONCT 40/100 Developing
369 Belite Bio, Inc BLTE 40/100 Developing
370 uniQure N.V. QURE 40/100 Developing
371 Viking Therapeutics, Inc. VKTX 40/100 Developing
372 Abeona Therapeutics Inc. ABEO 40/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How ONCT scores on the Corporate Default defenses

Pricing Power

Score 19 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 22 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 44 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 78 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 53 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 14 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ONCT's moat

What is Oncternal Therapeutics, Inc.'s moat score?

Oncternal Therapeutics, Inc. (ONCT) scores 40 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #368 of 713 scored companies in Biotechnology, the top 52%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Capital Efficiency (78/100) and its weakest is Scale & Market Position (14/100).

How does Oncternal Therapeutics, Inc. compare with other Biotechnology companies?

Oncternal Therapeutics, Inc. ranks #368 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are BeyondSpring, Inc. (BYSI) at 40 just above it and Belite Bio, Inc (BLTE) at 40 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Oncternal Therapeutics, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Oncternal Therapeutics, Inc.?

The Corporate Default template measures 6 defenses, and ONCT scores: Pricing Power (19), Cost Advantage (22), Customer Stickiness (44), Capital Efficiency (78), Resilience (53), Scale & Market Position (14). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000